Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224334 · ClinicalTrials.gov registry record · Phase 1
Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.
A Phase 1 study of Diabetes (DM), sponsored by David D'Alessio, M.D..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07224334 is a Phase 1 study of Diabetes (DM) that is actively recruiting participants, run by David D'Alessio, M.D.. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07224334, a Phase 1 study of Diabetes (DM), is actively recruiting participants, sponsored by David D'Alessio, M.D..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Glucagon secretion from α-cells has long been viewed as primarily a counterregulatory mechanism - e.g. an agent with a role to prevent blood sugar from decreasing to levels that compromise function. Our group, along with other researchers, have begun to identify a much more complex role for α-cells, raising questions about when and how glucagon may influence blood glucose levels. This proposal looks to detail proglucagon peptide secretion from α-cells and the impact this has on β-cell function and glucose tolerance, in preclinical studies of human islets and translational studies in human subjects. This protocol registration describes Aim 2 from this NIH grant which involves 2 study populations and separate protocols but addresses a common question. Aim 3 in the grant is focused on a separate hypothesis and will be conducted and published separately from Aim 2.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min
Study Locations (1)
North Carolina
- Duke Center for Living - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-12-30 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07224334
The ClinicalTrials.gov registry entry for NCT07224334 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is David D'Alessio, M.D., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes (DM) appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone is the first listed.
NCT07224334 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT07224334 about?
NCT07224334 is a clinical study titled "Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.". Glucagon secretion from α-cells has long been viewed as primarily a counterregulatory mechanism - e.g. an agent with a role to prevent blood sugar from decreasing to levels that compromise function. Our group, along with other researchers, have begun to identify a much more complex role for α-cells,...
What is the current status of trial NCT07224334?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-12-30. Estimated completion is 2027-12.
What conditions does trial NCT07224334 study?
This clinical trial studies the following conditions: Diabetes (DM).
What interventions are being tested in trial NCT07224334?
The interventions under investigation include: Dexamethasone (DRUG), Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min (DRUG).
Who is sponsoring clinical trial NCT07224334?
This trial is sponsored by David D'Alessio, M.D., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07224334 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes (DM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.